March 8th 2024
The surprise request for review of the phase 3 TRAILBLAZER-ALZ-2 clinical trial findings will delay the original PDUFA timing beyond first quarter 2024.
Cardiometabolic Diseases and Dementia Risk Show Dose-dependent Relationship in Large Twin Study
January 13th 2023For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.